Nuvox Pharma, L.L.C.
Tucson, AZ
- UEI
- WHNYG96UDLJ8
- CAGE
- 51P42
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 1635 E 18th St, Tucson, AZ 85719, USA
- Website
- nuvoxtherapeutics.com
- Founded
- 2008
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | -$393,000 |
| FY2024 | $0 |
| FY2023 | $749,448 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Triterpenoid Therapeutics Inc. | Boston, MA | 813920 Professional Organizations |
| Nushores Biosciences LLC | Little Rock, AR | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Truspin Nanomaterial Innovation, Inc. | Birmingham, AL | 325220 Artificial and Synthetic Fibers and Filaments Manufacturing |
| Superior Nano LLC | Saint Paul, MN | 325412 Pharmaceutical Preparation Manufacturing |
| Nanolab, Inc. | Waltham, MA | 541713 Research and Development in Nanotechnology |
About the company
Nuvox Pharma, L.L.C. is a small disadvantaged business registered in SAM.gov since 2008, located in Tucson, Arizona, structured as a limited liability partnership. The company specializes in developing innovative oxygen therapeutic nanotechnology (NANO2) with a focus on medical research and therapeutic interventions for critical medical conditions. Through its federal contract and grant awards, Nuvox Pharma demonstrates expertise in research and development of advanced medical technologies targeting complex diseases such as COVID-19, stroke, and cancer.
The company's federal contract work is primarily focused on research and development services. Its sole current federal contract, awarded by the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, is a $749,447.48 definitive, firm-fixed price contract for developing novel oxygen therapeutic nanotechnology (NANO2) for COVID-19 treatment. The contract, which extends previous research under Announcement of Opportunity #19, does not have a specific set-aside designation and has an ultimate completion date of May 31, 2025.
Nuvox Pharma has secured multiple federal grant awards across different agencies, focusing on advanced medical research. These grants include a $919,366 project grant from the National Cancer Institute to evaluate liquid biopsy approaches for glioblastoma patients, a cooperative agreement with the National Institute of Neurological Disorders and Stroke to develop NANO2 as a cerebroprotectant in ischemic stroke, and a project grant from the Defense Health Agency to explore NANO2's potential in enhancing immunotherapy for triple-negative breast cancers. The grant awards collectively demonstrate the company's commitment to developing innovative therapeutic technologies across various critical medical domains, with research periods ranging from 2021 to 2027.
Quick answers
Is Nuvox Pharma, L.L.C. registered in SAM.gov?
Yes. Nuvox Pharma, L.L.C.'s SAM.gov registration is active through January 7, 2027.
What is Nuvox Pharma, L.L.C.'s CAGE code?
Nuvox Pharma, L.L.C.'s CAGE code is 51P42, and its Unique Entity ID (UEI) is WHNYG96UDLJ8.
How much has Nuvox Pharma, L.L.C. received in federal contracts?
Federal contracts obligated $356,448 to Nuvox Pharma, L.L.C. in fiscal years 2023 through 2027.
What is Nuvox Pharma, L.L.C.'s most recent federal award?
Nuvox Pharma, L.L.C.'s most recent federal grant award is Liquid biopsy in glioblastoma treated with chemoradiation and an oxygen therapeutic - hypothesis and specific aims… (R44CA298498), from National Cancer Institute (NIH), on September 22, 2025.
On GovTribe
See Nuvox Pharma, L.L.C.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors